MedTrace Logo

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea

NCT02583009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2016-09-20

No results posted yet for this study

Summary

This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.

Conditions

  • Rosacea

Interventions

DRUG

PAC-14028 cream 0.1%

Topical application

DRUG

PAC-14028 cream 0.3%

Topical application

DRUG

PAC-14028 cream 1.0%

Topical application

DRUG

PAC-14028 cream vehicle

Topical application

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • Miyoung Park, PhD · Amorepacific R&D Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583009 on ClinicalTrials.gov